氣喘市場：KOL洞察

本報告深入探討了不斷發展的氣喘治療領域，提供了頂級 KOL 對氣喘治療的最新見解，包括 GSK 的depemoximab、Tezspire 的市場動態和 dexpramipexole 等新療法，強調了最近臨床試驗的主要發現以及新療法對當前實踐的影響。

報告內容

• 未來 3 至 5年影響氣喘治療的重大變化
• 進行中的臨床試驗將如何影響Amgen/AstraZeneca抗 TSLP 單株抗體 Tezspire 的未來使用？
• 抗 IL5 療法和 Dupixent 是治療嚴重氣喘的成熟生物製劑，但 GSK 的長效抗 IL5 藥物 depemoximab 能帶來多大的顛覆性？
• 專家認為GSK的Trelegy Ellipta、Novartis的Enerzair Breezhaler 和 Chiesi 的Trimbow 這三重組合方案在治療氣喘方面有何作用，AstraZeneca的Breztri/Trixeo Aerosphere 是否也有潛在作用？
• KOL 如何評估Sanofi口服 BTK 抑制劑 rilzabrutinib 影響氣喘治療實務的可能性？
• 專家如何評估 Knopp Biosciences 的口服多巴胺受體促效劑 dexpramipexole 在 III 期試驗 EXHALE-2、-3 和 -4 中治療氣喘患者的成功幾率？

主要品牌

Explore the latest insights from top KOLs on asthma therapies, including GSK's depemokimab, Tezspire's market dynamics, and novel treatments like dexpramipexole. This report delves into the evolving landscape of asthma treatment, highlighting key findings from recent clinical trials and the impact of emerging therapies on current practice.

Key Questions Answered:

• What will be the major changes to impact the treatment of asthma over the next three to five years?
• How could ongoing clinical trials impact the future use of Amgen/AstraZeneca's anti-TSLP monoclonal antibody Tezspire?
• The anti-IL5 therapies and Dupixent are well-established biologics for severe asthma, but just how disruptive could GSK's long-acting anti-IL5 agent depemokimab be?
• How do experts view the role of fixed-dose triple-combination therapies (GSK's Trelegy Ellipta, Novartis' Enerzair Breezhaler and Chiesi's Trimbow) in asthma, and could AstraZeneca's Breztri/Trixeo Aerosphere find a role?
• How do the KOLs assess the prospects for Sanofi's oral BTK inhibitor rilzabrutinib to impact asthma treatment practice?
• With the Phase III EXHALE-2, -3 and -4 trials evaluating Knopp Biosciences' dexpramipexole in the treatment of patients with asthma, how do experts weigh up this oral dopamine receptor agonist's prospects for success?

Key Brands:

Partial List of Participating Experts:

• Professor of Pediatrics, Allergy/Immunology/Pulmonary Medicine, Scientific Director of the Center for Clinical and Translational Research, Vanderbilt University Medical Center, USA
• Professor of Medicine (Pulmonary, Critical Care and Sleep Medicine), Yale School of Medicine, USA
• Clinical Professor of Medicine, University of Medicine and Dentistry of New Jersey - Rutgers, Director of Clinical Research at Pulmonary and Allergy Associates, USA
• Professor of Thoracic Medicine and Head of Respiratory Medicine at the National Heart and Lung Institute and Honorary Consultant Physician at Royal Brompton Hospital, Senior Research Investigator at Imperial College, UK
• Head of Pulmonology, Consultant and Professor of Respiratory Medicine at Arnaud de Villeneuve Hospital/University of Montpellier, France
• Head of Department of Allergy, La Paz University Hospital, IdiPAZ, CIBER of Respiratory Diseases (CIBERES), Universidad Autenoma de Madrid, Spain

Methodology

Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.